ASND
Ascendis Pharma A/S
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
No thesis.
Ascendis Pharma A/S
251.31
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | RA Capital ManagementRA Capital Management | $2.7B | 15.20% | 0.00% | |
| 2 | T. Rowe Price Investment ManagementT. Rowe Price | $1.8B | 9.98% | +9.62% | |
| 3 | venBio Select AdvisorvenBio Select Advisor | $1.4B | 7.55% | +0.96% | |
| 4 | Westfield Capital ManagementWestfield | $1.3B | 7.09% | −0.32% | |
| 5 | Jupiter TopcoJupiter Topco | $973.4M | 5.39% | — | |
| 6 | FMRFMR | $945.7M | 5.24% | −8.54% | |
| 7 | Artisan Partners Limited PartnershipArtisan Partners Limited Partnership | $702.5M | 3.89% | −18.46% | |
| 8 | BlackRockBlackRockindex-like | $589.9M | 3.27% | new | |
| 9 | Capital International InvestorsCapital International Investors | $530.4M | 2.94% | +1.52% | |
| 10 | Massachusetts Financial ServicesMassachusetts Financial Services | $500.1M | 2.77% | +0.79% | |
| 11 | Franklin ResourcesFranklin Resources | $496.8M | 2.75% | −9.23% | |
| 12 | Wellington Management GroupWellington | $413.1M | 2.29% | new | |
| 13 | American Century CompaniesAmerican Century Companies | $373.6M | 2.07% | new | |
| 14 | Perceptive AdvisorsPerceptive | $310.4M | 1.72% | −24.01% | |
| 15 | T. Rowe Price AssociatesT. Rowe Price | $299.4M | 1.66% | −26.65% | |
| 16 | Capital World InvestorsCapital World Investors | $241.7M | 1.34% | new | |
| 17 | Principal Financial GroupPrincipal Financial | $233.0M | 1.29% | −2.55% | |
| 18 | Polar Capital HoldingsPolar Capital | $164.5M | 0.91% | −5.34% | |
| 19 | Goldman Sachs GroupGoldman Sachs | $149.2M | 0.83% | −1.18% | |
| 20 | Morgan StanleyMorgan Stanley | $145.2M | 0.80% | new | |
| 21 | State StreetState Streetindex-like | $137.1M | 0.76% | +488.51% | |
| 22 | InvescoInvesco | $110.5M | 0.61% | new | |
| 23 | Citadel AdvisorsCitadel | $108.5M | 0.60% | +501.76% | |
| 24 | Geode Capital ManagementGeodeindex-like | $107.5M | 0.60% | +452.71% | |
| 25 | UBS GroupUBS | $107.2M | 0.59% | +93.83% |
313 managers report $18.0B of Ascendis Pharma A/S on form 13F for the quarter ended Jun 30 '26. 22 of them hold 80% of it; RA Capital Management is largest at 15.20%.
News
Linked news
Expected move
No implied move.
No implied move.
No implied move.